The FML-vaccine (Leishmune®) against canine visceral leishmaniasis: A transmission blocking vaccine

Elvira M. Saraiva, André De Figueiredo Barbosa, Fernanda Nunes Santos, Gulnara Patrícia Borja-Cabrera, Dirlei Nico, Lucieri Olegário Pereira Souza, Carolina De Oliveira Mendes-Aguiar, Edilma Paraguai De Souza, Patrícia Fampa, Luciana Ellner Parra, Ingrid Menz, Jaime Galvão Dias, Sandra Maria De Oliveira, Clarisa Beatriz Palatnik-De-Sousa

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

83 Citas (Scopus)

Resumen

Transmission blocking vaccines are one of the control strategies for vector-transmitted protozoan diseases. Antibodies raised in the vaccinated host prevent the development of the parasite in the insect vector, interrupting the epidemiological cycle. The FML antigen of Leishmania donovani in combination with saponin (FML-vaccine and Leishmune®) induced 92-97% of protections against zoonotic visceral leishmaniasis. We assayed the ability of FML to inhibit Leishmania donovani and Leishmania chagasi procyclic promastigote-binding to dissected Lutzomyia longipalpis midguts. We found a dose-dependent inhibition, more pronounced on L. donovani (80%) than on L. chagasi promastigotes (p < 0.001). On the other hand, the Fab-IgG serum fraction of Leishmune® vaccinated dogs (IgG2 predominant), also inhibited parasite binding in a dose-response (p < 0.0001) with an equally potent effect against L. donovani or L. chagasi (p = 0.061). The transmission blocking properties of the Leishmune® vaccine was also assessed by an in vivo membrane assay, with sand flies fed with 1.5 × 107 amastigotes, human blood and, vaccinated or normal control dog sera. Significantly higher values were found in rate of infection (p < 0.025) and intensity of infection (number of parasites/insect) (p < 0.05) of control sand flies, making a very reduced infection index (20.7%) in the vaccine group. Our results disclosed that the Leishmune® vaccine is a TBV, and that the dog antibodies present in sera, even 12 months after vaccination, lead to a significant effective protection of 79.3%.

Idioma originalInglés
Páginas (desde-hasta)2423-2431
Número de páginas9
PublicaciónVaccine
Volumen24
N.º13
DOI
EstadoPublicada - 20 mar. 2006
Publicado de forma externa

Huella

Profundice en los temas de investigación de 'The FML-vaccine (Leishmune®) against canine visceral leishmaniasis: A transmission blocking vaccine'. En conjunto forman una huella única.

Citar esto